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 ABSTRACT 
 
The prognosis of the most common glial tumors, the glioblastoma (GBM; World Health 
Organization grade IV), remains poor with a 2-year survival rate in less than 20% of the patients 
despite significant advances in therapeutic options available. The dependence of tumor growth and 
metastasis on angiogenesis has provided powerful rationale for anti-angiogenic approaches to 
cancer therapy (Folkman J. 1971; Carmeliet P. et al. 2000). 
The main aim of this project was the characterization of tumour response to anti-angiogenic therapy 
and to find out new markers and better therapies to treat them.  
In a previous study we have demonstrated the role of Integrin Linked Kinase-1 (ILK-1), a kinase 
involved in cell cycle progression, inhibition of apoptosis, cell growth and migration, in the 
resistence of glioma to anti-angiogenic drugs. In fact, we found that the expression level of this 
protein decreases in the first part of the anti-angiogenic treatment and increases after 20 days of 
treatment in an in vivo model of glioblastoma. 
In addition we found that the expression levels of ILK-1 correlate with the worst outcome in 
patients. 
We demonstrated a strong reduction of tumour growth after the silencing of ILK-1 in our in vivo 
model. We want to analyze the effects of a small specific inhibitor of ILK-1: QLT0267 alone or in 
combination with two anti-angiogenic drugs already used in clinic: sorafenib and sunitinib that 
inhibit tyrosine kinase receptors. The combination of the pharmacologic inhibition of ILK-1 and 
angiogenesis lead to a significant decrease of tumour volume and vessels formation. 
We than investigated the molecular mechanism underling the effect of the combination of the 
inhibition of angiogenesis and ILK-1 studying what pathway is implicated. We speculate that the 
inhibition of tyrosine kinase receptors and the ILK-1 activity lead, through AKT pathway, to a 
downregulation of the pathways involved in angiogenesis. Interestingly, we found a strong decrease 
in glioma cells of HIF-1α protein after the combined treatments and we think that this can be related 
to the effects on vessel formation and on tumour growth that we have observed in vivo. 
Our data taken together indicate that the combinatorial administration of compounds that 
simultaneously inhibit angiogenesis and tumor cell proliferation by targeting specific signaling 
pathways might results in a significant increase in the therapeutic efficacy. 
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 1 INTRODUCTION 
 
 
1.1 CNS TUMORS 
 
Several different types of tumors, benign and malignant, have been identified in the central 
nervous system (CNS). The prognoses for these tumors are related to several factors, such as the 
age of the patient and the location and histology of the tumor. In adults, about half of all CNS 
tumors are malignant, whereas in pediatric patients, more than 75% are malignant. For most 
benign CNS tumors that require treatment, neurosurgeons can offer curative resections or at least 
provide significant relief from mass effect. Unfortunately, we still lack effective treatments for 
most primary and secondary malignant CNS tumors. However, the past decade has witnessed an 
explosion in the understanding of the early molecular events in malignant primary CNS tumors, 
and for the first time in history, oncologists are seeing that a plethora of new therapies targeting 
these molecular events are being tested in clinical trials. There is hope on the horizon for the fight 
against these deadly tumors (Adamson, Rasheed et al.). 
A glioma is a type of tumor that starts in the brain or spine. It is called glioma because it arises 
from glial cells. A number of studies have investigated molecular subclasses in Gliomas. There 
are numerous grading systems in use, the most common is the World Health Organization (WHO) 
grading system that distinguishes four different grades of gliomas based on the pathologic 
evaluation of the tumor. According to this grading system, tumours are graded from I (least 
advanced disease— best prognosis) to IV (most advanced disease—worst prognosis). 
• Low-grade gliomas [WHO grade II] are well-differentiated (not anaplastic); these are not 
benign but still portend a better prognosis for the patient.  
• High-grade [WHO grade III-IV] gliomas are undifferentiated or anaplastic; these are 
malignant and carry a worse prognosis (anaplastic astrocytoma and glioblastoma)(Louis, 
Ohgaki et al. 2007).	   
Grade I tumors are biologically benign and can be cured if they can be surgically resected; grade 
II tumors are low-grade malignancies that may follow long clinical courses, but early diffuse 
infiltration of the surrounding brain renders them incurable by surgery; grade III tumors exhibit 
increased anaplasia and proliferation over grade II tumours and are more rapidly fatal;	  grade IV 
tumours exhibit more advanced features of malignancy, including vascular proliferation and 
necrosis, and as they are recalcitrant to radio/chemotherapy they are generally lethal within 12 
month. 
1.1.2 Glioblastoma Multiforme 
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Glioblastoma multiforme (GBM, WHO grade IV) is the most frequent malignant tumour of the 
central nervous system (CNS) representing up to 50% of all primary brain gliomas, accounts for 
approximately 12-15% of all brain tumors and is one of the most lethal cancers in adults and 
children; the prognosis of patients with GBM remains poor (Ohgaki, Dessen et al. 2004). Despite 
aggressive treatments with surgery, radiation, and chemotherapy, median survival is less than 15 
months and overall survival is less than 10% at 5 years. The treatment difficulty is due to the 
exceptionally infiltrative nature of GBM and its proclivity to integrate into normal brain tissue. To 
date, the management of patients with GBM continues to harbor significant challenges, and 
comprehensive genetic screens of tumor tissues and signaling pathways have been explored to 
develop molecular based targeted therapies. 
Significantly, expression profiling studies have revealed that molecular classification of gliomas 
may be of prognostic value (Phillips, Kharbanda et al. 2006). 
1.1.3 Molecular Characterization of GBM 
 
GBM is a highly anaplastic and morphologically highly heterogeneous tumor. As reflected in the 
old moniker “multiforme”, GBM presents with significant intratumoral heterogeneity on the 
cytopathological, transcriptional, and genomic levels. The diagnosis of GBMs has been based on 
a complete clinicopathological assessment and this has been an extremely valuable approach. The 
pathognomonic features that characterize GBM at the tissue level are the presence of areas of 
necrosis with surrounding pseudopalisades and microvascular hyperplasia, which are believed to 
be instrumental to its accelerated growth. Anaplastic astrocytomas are characterized by increased 
cellularity, nuclear atypia, and mitotic activity. Glioblastomas also contain areas of microvascular 
proliferation or necrosis. All of these tumors may contain perinuclear halos and a delicate network 
of branching blood vessels (chicken-wire pattern)(Louis, Ohgaki et al. 2007). Malignant gliomas 
typically contain both neoplastic and stromal tissues, which contribute to their histologic 
heterogeneity and variable outcome (Phillips, Kharbanda et al. 2006). In the last years there has 
been important progress in the understanding of the molecular pathogenesis of malignant gliomas, 
and especially the importance of cancer stem cells; this is important taking into account that 
malignant transformation in gliomas results from the sequential accumulation of genetic 
aberrations and the deregulation of growth-factor signaling pathways (Furnari, Fenton et al. 
2007). Glioblastomas can be separated into two main subtypes on the basis of biologic and genetic 
differences Primary glioblastomas typically occur in patients older than 50 years of age and are 
characterized by EGFR amplification and mutations, loss of heterozygosity of chromosome 10q, 
deletion of the phosphatase and tensin homologue on chromosome 10 (PTEN), and p16 deletion. 
Secondary glioblastomas are characterized by mutations in the p53 tumorsuppressor gene, 
overexpression of the platelet derived growth factor receptor (PDGFR) (Watanabe, Tachibana et 
al. 1996), abnormalities in the p16 and retinoblastoma (Rb) pathways, and loss of heterozygosity 
of chromosome 10q. Secondary glioblastomas have transcriptional patterns and aberrations in the 
DNA copy number that differ markedly from those of primary glioblastomas. Despite their 
genetic differences, primary and secondary glioblastomas are morphologically indistinguishable 
and respond similarly to conventional therapy, but they may respond differently to targeted 
molecular therapies (Ohgaki and Kleihues 2007). 
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1.1.4 Pathways Alterations 
 
Analysis of GBM genome and signaling pathways, revealed that genetic loss is scattered across 
the entire genome, affecting almost all chromosomes. The common genetic alterations include 
epidermal growth factor receptor (EGFR) amplification, mutations in TP53, P16, DCC and RB, 
and deletions associated with chromosomes 19q and 22q, chromosome 7 gain and chromosome 
10 loss. 
 
Cell cycle dysregulation and enhanced cell proliferation 
The RB pathaway. Gliomas circumvent RB-mediated cell cycle inhibition through any of several 
genetic alterations. The Rb1 gene, which maps to chromosome 13q14, is mutated in almost 25% 
of high-grade astrocytomas and the loss of 13q typifies the transition from low- to intermediate-
grade gliomas (Henson, Schnitker et al. 1994) Moreover, amplification of the CDK4 gene on 
chromosome 12q13-14 accounts for the functional inactivation of RB in 15% high-grade gliomas, 
and CDK6 is also amplified but at a lower frequency (Costello, Plass et al. 1997). RB activity is 
also frequently lost through the inactivation of a critical negative regulator of both CDK4 and 
CDK6, p16Ink4a (Serrano, Hannon et al. 1993). The importance of the inactivation of the RB 
pathway in glioma progression is evidenced by the near-universal and mutually exclusive 
alteration of RB pathway effectors and inhibitors in both primary and secondary GBM. However,	  
the neutralization of this pathway alone is insufficient to abrogate cell cycle control to the extent 
needed for cellular transformation, suggesting that other important cell cycle regulation pathways 
complement its activities in preventing gliomagenesis (Huang, Baldwin et al. 2002). 
The p53 pathway. The p53 signaling pathway has been suggested to be an essential molecular 
pathway in regulating glioma oncogenesis and is one of the most frequently mutated tumor 
suppressors in human gliomas. The p53 tumor suppressor prevents the propagation of cells with 
unstable genomes, predominantly by halting the cell cycle in the G1 phase or instigating a 
program of apoptosis or proliferative arrest (Vousden and Lu 2002).	   Mutant p53 is closely 
associated with the hallmarks of cancer (Solomon, Madar et al.). p53 mutations may not only 
have lost tumor-suppressive functions but may have also acquired pro-oncogenic properties, 
which are known as “gain-of-function” activities (Sigal and Rotter 2000). Mutant p53 can 
attenuate the expression of classical wild type p53 responsive target genes, including PTEN, p21, 
and gadd45 (Vikhanskaya, Lee et al. 2007).	  p53 was found to activate glycogen synthase kinase-
3β(GSK-3 β) by directly binding to this protein (Watcharasit, Bijur et al. 2002). 
Mitogenic signaling pathways. Many mitogens and their specific membrane receptors are present 
in overactive form in gliomas Proliferation of normal cells requires activation of mitogenic 
signaling pathways through diffusible growth factor binding, cell–cell adhesion, and/or contact 
with extracellular matrix (ECM) components. These signals are transduced intracellularly by 
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transmembrane receptors that typically activate the PI3K and MAPK signaling pathways. In 
contrast, tumor cells acquire genomic alterations that greatly reduce their dependence on 
exogenous growth stimulation, enabling their inappropriate cell division, survival, and motility 
through the constitutive activation of these pathways. While gliomas overcome the normal 
impositions on the control of mitogenic signaling through multiple mechanisms, activation of 
receptor tyrosine kinases (RTKs) appears to be the predominant mechanism. Among the pathway, 
it is important to notice  (the most important??) the MAPK pathway that is activated by both 
integrins and RTKs, the PI3K/PTEN/AKT pathway. Recent studies emphasize the complexity of 
cross-talk between the Ras/MAPK and PI3K pathways (Courtois-Cox, Genther Williams et al. 
2006). The complicated interplay among these critical molecules highlights the need for detailed 
dissection of the pathways that are aberrant in each tumor to accurately guide the choice of 
combination therapies that can simultaneously target multiple pathways. 
Epidermal growth factor receptor (EGFR) is a transmembrane receptor TK of the ErbB (also 
known as HER) family that is abnormally activated in many epithelial tumors. Several 
mechanisms lead to aberrant receptor activation, including receptor overexpression, gene 
amplification, activating mutations, overexpression of receptor ligands, and/or loss of their 
negative regulatory mechanisms (Baselga and Arteaga 2005). Half of the tumors with EGFR 
amplification express a constitutively autophosphorylated variant of EGFR, known as EGFRvIII, 
that lacks the extracellular ligand-binding domain (exons 2 through 7) (Pelloski, Ballman et al. 
2007). Recently, activating mutations in the extracellular domain of EGFR have been identified 
(Lee, Vivanco et al. 2006).	  Immunohistochemical studies have demonstrated that GBM could be	  
stratified according to PI3K pathway activation status and that these activation profiles are 
associated with EGFRvIII expression and PTEN loss (Choe, Horvath et al. 2003).	  Consistent with 
enhanced apoptosis resistance by EGFRvIII, activated EGFR has also been shown to confer radio- 
and chemo-resistance to GBM cells (Chakravarti, Chakladar et al. 2002).                                                                                                              
Thus, EGFR has been a prime target for therapeutic intervention in GBM with differents 
approaches and the development of sensitive methodologies to monitor the EGFR pool before and 
during therapy will constitute an important step in advancing the current use of EGFR kinase 
inhibitors for cancer. 
Platelet derived growth factor receptor (PDGFR) In addition to the EGFR signaling axis, 
PDGFRα and its ligands, PDGF-A and PDGF-B, are expressed in gliomas, particularly in high 
grade tumors, while strong expression of PDGFRβ occurs in proliferating endothelial cells in 
GBM (Westermark, Heldin et al. 1995). In contrast to EGFR, amplification or rearrangement of 
PDGFRα is much less common, and a relatively rare oncogenic deletion mutation of PDGFRα 
(loss of exons 8 and 9) has been described that, similar to EGFRvIII, is constitutively active and 
enhances tumorigenicity (Clarke and Dirks 2003). The PDGF signaling is a key regulator of glial 
development, and both ligand and receptors are frequently expressed in gliomas, creating an 
autocrine loop that stimulates proliferation of the tumor. 
Growth factor–receptor signaling, through intermediate signal-transduction generators, results in 
the activation of transcriptional programs for survival, proliferation, invasion, and angiogenesis. 
Common signal-transduction pathways activated by these growth factors are the Ras–mitogen- 
activated protein (MAP) kinase pathway, which is involved in proliferation and cellcycle 
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progression, and the phosphatidylinositol 3-kinase (PI3K)–Akt–mammalian target of rapamycin 
(mTOR) pathways, which are involved in the inhibition of apoptosis and cellular proliferation 
(Furnari, Fenton et al. 2007). A explanation for the failure of EGFR and PDGFR inhibitors to 
elicit significant clinical outcomes is that additional RTKs may cooperate to provide a signaling 
threshold that prevents the inhibition of mitogenic and survival signals through the inactivation of 
any single RTK. It has been demonstrated that multiple RTKs in addition to EGFR and PDGFR 
are activated simultaneously in primary GBM patient samples (Stommel, Kimmelman et al. 
2007). The discovery of receptor coactivation or cooperation suggests that tumor RTK profiling 
may be an important step in the development of a personalized GBM therapeutic regimen. 
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Fig 1 Cancer pathways. Genetic alterations characteristic of astrocytic glioma lead to aberrant activation of key pathways 
involved in mitogenic signaling and cell cycle control. In green are shown proto-oncogenes activated by mutation and growth-
promoting genes that are commonly overexpressed; in red are shown tumor suppressor genes that are lost or inactivated; in the 
blue boxes are drugs that specifically target these pathways. From (Furnari, Fenton et al. 2007). 
 
Apoptosis 
A hallmark feature of malignant glioma cells is an intense resistance to death-inducing stimuli 
such as radio-therapy and chemotherapy. This biological property has been linked to genetic 
alterations of key regulatory molecules involved in mitogenic signalling, as well as regulatory and 
effector molecules residing in cell death networks of both extrinsic (death receptor-mediated) and 
intrinsic (mitichondria-dependent) apoptosis signaling pathways. The most important death 
receptor systems include TNFR1 (DR1/CD120a), TRAILR1 (DR4/APO-2), TRAILR2 
(DR5/KILLER/TRICK2), and CD95 (DR2/Fas/APO-1), they are cell surface molecules that,upon 
binding their cognate ligands, recruit adapter molecules for the autoproteolytic processing and 
activation of caspase (Lavrik, Golks et al. 2005). Several lines of evidence support important roles 
of these death receptors in glioma pathogenesis (Steinbach and Weller 2004). The expression 
levels of these death receptors and in particular of their corresponding (antagonistic) decoy 
receptors may correlate with susceptibility of glioma cells to death ligand-induced apoptosis. 
Necrosis 
While highly resistant to therapeutic apoptotic stimuli, GBM tumor cells exhibit the paradoxical 
propensity for extensive cellular necrosis. Indeed, necrosis is the most prominent form of 
spontaneous cell death in GBM, presented as foci of micronecrosis surrounded by broad 
hypercellular zones contiguous with normal tissue or by parenchymal infiltrates; in GBM, the 
presence of necrosis is an important diagnostic feature, clinical studies indicate that as the degree 
of necrosis advances, the patient's prognosis worsens. While limited blood supply and anoxia due 
to a microthrombotic process has been identified as an important cause of necrosis, the molecular 
basis for this necrotic phenotype, particularly in the context of intense apoptotic therapy 
resistance, has recently come into focus with the discovery and characterization of the Bcl2-like 
12 (Bcl2L12) protein. One of the many possible pathways leading to necrosis formation may 
involve increased tumor cell secretion of tumor necrosis factor. Procoagulation and antiapoptotic 
mechanisms resulting from certain pathways could prevent the completion of tumor necrosis 
factor-induced apoptosis and could promote necrosis as the final mode of cell death (Raza, Lang 
et al. 2002). While limited blood supply and anoxia due to a microthrombotic process has been 
identified as an important cause of necrosis, the molecular basis for this necrotic phenotype, 
particularly in the context of intense apoptotic therapy resistance, has recently come into focus 
with the discovery and characterization of the Bcl2-like 12 (Bcl2L12) protein. Bcl2L12 has been 
shown to be a potent inhibitor of post-mitochondrial apoptosis signal transduction that is 
significantly overexpressed in primary GBMs (Stegh, Kim et al. 2007). The anti-apoptotic actions 
of Bcl2L12 relate significantly to its capacity to neutralize effector caspase activity downstream 
from mitochondrial dysfunction. These activities of Bcl2L12 are highly relevant to the necrotic 
process, in fact suppression of caspase activity downstream from mitochondria redirects the death 
program from apoptosis to necrosis. 
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1.2 ANGIOGENESIS 
 
Angiogenesis and tumor cell invasion play a critical role in glioma development and growth, even 
during the earliest phases (Bello, Giussani et al. 2004).	  Indeed, the formation of abnormal tumor 
vasculature and glioma cell invasion along white matter tracts are proposed to be the major causes 
of the therapeutic resistance of these tumors; thus, glioma remains a fatal disease despite advances 
in surgical and medical therapy. Glioma tumors are an example of highly vascularized tumors, 
which induce angiogenesis by upregulating Vascular Endothelial Growth Factor (VEGF) and its 
downstream pathways. Indeed, several molecular abnormalities have been described in glioma 
that promote angiogenesis, such as mutations and/or upregulation of PI3K/Akt and the VEGF 
receptor (VEGFR) in the glioma endothelium (Plate, Breier et al. 1994). Interestingly, each of 
these signaling pathways involves alterations that can be therapeutically targeted (Duda, 
Batchelor et al. 2007). Evaluation of drugs that target these pathways requires novel preclinical 
and clinical experimental trial design to define the optimal drug dose and delivery times to avoid 
toxicity during the first months of treatment (Bertolini, Shaked et al. 2006; Duda, Cohen et al. 
2007) Furthermore, whether these agents can be used in combination with classical cytotoxic 
chemotherapy, what molecular markers can predict response and whether they can be potentiated 
by such combinatorial treatments are important issues that remain to be explored.  
1.2.1 Angiogenesis in glioma 
 
Angiogenesis, the formation of new blood vessels, is a critical step during tumorigenesis and 
represents a pathological hallmark of cancer. When a solid tumor, such as a brain tumor, grows 
larger than a critical size (1–2 mm in diameter), it must recruit new blood vessels to supply the 
required oxygen and nutrition levels necessary for its survival and proliferation. This process 
comprises the formation of new blood vessels from pre-existing ones and is a crucial step in the 
progression of cancer from a small and localized neoplasm to a highly aggressive tumor.  
Angiogenesis plays a crucial role in glioma development and growth (Bello, Giussani et al. 2004). 
Gliomas are highly vascularized tumors and neovascularization in and around the tumor are well 
characterized. Holash et al reported also vascular cooption before the real amgiogenesis in a 
experimental model of glioma (Holash, Maisonpierre et al. 1999). The level of angiogenesis is 
correlated with the aggressiveness of gliomas and is often associated with prognosis. 
Glioblastomas (GBM) are the most lethal cancer and the most vascularized brain cancer, with the 
highest degree of vascular proliferation and endothelial cell hyperplasia (Brem, Cotran et al. 
1972). Patients with high tumor microvascular densities exhibit shorter postoperative survival 
rates than patients with low microvascular densities (Leon, Folkerth et al. 1996; Birlik, Canda et 
al. 2006). Perivascular migration, proliferation, and angiogenesis are closely associated and 
progress concurrently in gliomas. 
Neovascularization in and around the malignant glioma is well recognized. Glioblastoma, one of 
the most well-studied tumor types, with regard to angiogenesis, are known to have blood vessels 
of increased diameter with highly permeability, tickened basement membranes, and highly 
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proliferative endothelial cells. Such intense vascularization might be responsible for the 
peritumoral edem, one of the pathological feature of GBM. Angiogenesis requires three distinct 
steps: (1) blood vessel breakdown, (2) degradation of the vessel basement membrane and the 
surrounding extracellular matrix (ECM), and (3) migration of endothelial cells and the formation 
of new blood vessels (Onishi, Ichikawa et al.). The first step in forming new blood vessels from 
existing vessels is the dissolution of aspects of native vessels. Glioma cells first accumulate 
around the existing cerebral blood vessels and lift off the astrocytic foot processes, which leads to 
the disruption of the normal contact between endothelial cells and the basement membrane 
(Zagzag, Amirnovin et al. 2000). Degradation of the vessel basement membrane and surrounding 
ECM, which also facilitates the invasion of endothelial cells, is an integral part of the ongoing 
angiogenic process. The matrix metalloproteinase (MMP) family enzymes that degrade 
components of ECM consist of four groups according to their substrates: collagenases, 
gelatinases, stromelysins, and membrane-associated MMPs. Gelatinases-A (MMP-2) and 
gelatinases-B (MMP-9) are highly expressed in astrocytomas, and their expression levels, 
especially those of MMP-9, correlate with the histological grade of tumor. Both MMP-2 and 
MMP-9 have been detected in blood vessels as well as in tumor cells. MMP-2 and MMP-9 
expression is strongly induced by hypoxia, and these two molecules appear to have a synergistic 
effect on basement membrane degradation (Lakka, Gondi et al. 2005). After regression of existing 
vessels and breakdown of the basement membrane, endothelial cells proliferate and migrate 
toward the tumor cells expressing pro-angiogenic compounds. Integrin αvβ3 and αvβ1 are 
upregulated in endothelial cells during angiogenesis, enhancing endothelial cell adhesion and 
migration. In addition to migration of endothelial cells, migration of pericytes is an important part 
of tumor vessel formation. Platelet-derived growth factor (PDGF) secretion by activated 
endothelial cells recruits pericytes to the site of newly sprouting vessels and aids in establishing a 
new basement membrane (Brooks, Clark et al. 1994; Ferrara and Kerbel 2005). At least five 
distinct mechanisms of neovascularization in GBMs have been identified: i) vascular co-option, 
ii) angiogenesis, iii) vasculogenesis, iv) vascular mimicry, and v) glioblastoma-endothelial cell 
transdifferentiation. These mechanisms are not independent of one another, but rather are 
interlinked and are controlled, at least in part, by similar processes (Fig 2). 
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A Sprouting angiogenesis B Vasculogenesis
C Vessel co-option D Vascular mimicry E Tumor cell         EC differentiation
 
Fig 2.. Modes of vessel formation. Vessel formation can occur by sprouting angiogenesis (A), by vasculogenesis:the recruitment 
of bone-marrow-derived endothelial progenitor cells (EPCs) that differentiated into endothelial cells (B), by co-opting pre-existing 
vessels (C), by vascular mimicry, in witch tumor vessels are lined by tumor cells (D), tumor cells with cytogenetic abnormalities 
can originate endothelial cells (E). Modified from (Carmeliet and Jain). 
 
Vascular co-Option 
Is the first mechanism by which gliomas achieve their vasculature; this process involves 
organization of tumor cells into cuffs around normal microvessels. Holash et al were the first to 
definitively demonstrate vessel co-option. Early tumors were well vascularized through vessel co-
option, and it was not until approximately 4 weeks after implantation that, after vascular 
regression, a robust angiogenic response was seen at the viable tumor periphery. In the interim, 
the majority of tumor vasculature was co-opted from normal brain vasculature (Figure 2C). Co-
opted vessels have been shown to express angiopoietin-2 (ANG-2) (Holash, Maisonpierre et al. 
1999). At this stage, and in the presence of VEGF, angiogenic vessel sprouting occurs. Possible 
molecular links between hypoxia and vascular co-option include the up-regulation of ANG-2 by 
hypoxia through HIF-1–dependent mechanisms and the presence of a HIF-1 binding hypoxia 
response element location identified in the first intron of the ANG-2 gene (ANGPT2) (Das, Yeger 
et al. 2005). 
Angiogenesis  
Vascular co-option is followed by the development of new vessels from pre-existing ones (Figure 
2A), a process known as angiogenesis. This mechanism is integral to both physiological and 
pathological processes. Glioma-associated sprouting angiogenesis begins with an angiopoietin-
mediated breakdown of existing vessels. After vascular co-option, persistent up-regulation of 
ANG-2 and TIE-2 in endothelial and tumor cells promotes disruption of endothelial and 
perivascular cell junctions, resulting in vessel disruption . A key early event is the proteolysis of 
the basement membrane and extracellular matrix due to the activity of matrix metalloproteinases 
(MMPs). In the presence of ANG-2, VEGF promotes migration and proliferation of endothelial 
cells and stimulates sprouting of new blood vessels. Acquisition of the tip and stalk phenotypes 
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among endothelial cells exposed to proangiogenic stimuli involves the delta-like 4 (DLL-4)/Notch 
pathway. The final stages of angiogenesis involve capillary morphogenesis, mediated largely by 
integrins α3β1 and αvβ3, as well as by CD44.17 Activated endothelial cells secrete platelet-
derived growth factor (PDGF), which recruits pericytes to the newly formed vessel,18 aided by 
the ANG/TIE pathway. Negative feedback by endogenous antiangiogenic factors, as well as 
accumulation of extracellular matrix, may modulate the process of vascular modeling (Kalluri 
2003). The end result of the neoplastic angiogenic process is a characteristically abnormal 
vascular network, with dilated and tortuous vessels and abnormal branching and arteriovenous 
shunts, which can also lead to abnormal perfusion. GBMs in particular have immature 
vasculature, with excessive leakiness, that can contribute to the breakdown of the blood-brain 
barrier. In addition to physical disruption of existing vessels by lifting and displacement of 
astrocytic foot processes by glioma cells, induction of leakiness by VEGF and vesiculovacuolar 
organelles contribute to an abnormal blood-brain barrier in the setting of glioma (Nagy, Dvorak et 
al. 2007). The permeability of newly formed vascular channels is increased, compared with that 
of mature capillaries. Normal capillaries of the brain maintain the integrity of the blood-brain 
barrier, but the blood vessels of experimental and human brain tumors are structurally altered and 
have increased capillary permeability, in part due to lack of a basal lamina (resulting from 
persistent angiogenic stimuli leading to incomplete maturation). Several key pathways have been 
identified in the process of glioma-associated angiogenesis, including erythropoietin and its 
receptor, DLL4 and its receptor Notch, macrophage migration inhibitory factor (MIF), neuropilin-
2 (NRP2), placental growth factor (PlGF), and basic fibroblast growth factor (bFGF), among 
others. The most studied and best characterized factor is VEGF. 
Vasculogenesis  
Vasculogenesis involves differentiation of circulating bone marrow-derived cells (BMDCs) 
known as endothelial progenitor cells (EPCs) Figure 2B. VEGF, which has been shown to play a 
critical role in angiogenesis, also contributes to EPC migration and proliferation. Supporting a 
role for vasculogenesis in glioma neovascularization is the observation that impaired recruitment 
of BMDCs interferes with tumor growth (Ruzinova, Schoer et al. 2003). Although vasculogenesis 
by definition refers to differentiation of EPCs, accumulating evidence suggests that in addition to 
bone marrow-derived EPCs, bone marrow derived tumor-associated macrophages (TAMs) 
circulate in the blood and home to sites of pathological neovascularization and differentiate into 
endothelial cells or macrophages (Venneri, De Palma et al. 2007). 
Vascular Mimicry 
A fourth mechanism of glioma vascularization, vascular mimicry, is defined as the ability of 
tumor cells to form functional vessel-like networks (Figure 2D). Shaifer et al suggested a link 
between vascular mimicry in GBMs and vascular radioresistance (Shaifer, Huang et al.). Under 
angiogenic conditions, glioma cells formed threedimensional vascular networks, but 
characterization of these glioma cells consistently revealed the absence of endothelial-specific 
markers, suggestive of vascular mimicry. In a study of 101 human glioma samples, Liu et al 
found a correlation between vascular mimicry and World Health Organization tumor grade. 
Tumors that contained evidence of vascular mimicry, defined immunohistochemically as CD34–
PAS+, were more likely to be higher grade and more aggressive, and these patients had shorter 
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overall survival times than those without vascular mimicry. Interestingly enough, tumors 
exhibiting vascular mimicry had lower microvascular densities than those that did not, indicating 
that vascular mimicry provides a complementary neovascularization pathway (Liu, Zhang et al.). 
Glioblastoma-Endothelial cell Transdifferentiation 
The most recently described mechanism of glioma neovascularization involves 
transdifferentiation of glioma cells into an endothelial phenotype (Figure 2E). As with vascular 
mimicry, the hypothesis of endothelial transdifferentiation of tumor cells originated with human 
cutaneous melanoma models. The rather recent identification of glioma endothelial cell 
transdifferentiation has yet to be confirmed, and will need to be further investigated for complete 
validation. 
1.2.2 Role of hypoxia in Angiogenesis 
 
The role of hypoxia and HIF1α in vascular co-option has been discussed in the previous 
paragraph; but Hypoxia has a great role also in angiogenesis, vasculogenesis and in the 
differentiation of tumoral cells in endothelial cells. 
Hypoxia has long been known as a major stimulator of angiogenesis in GBMs. Angiogenic factors 
(many of which are up-regulated by hypoxia). In particular, VEGF, which is up-regulated by 
hypoxia, stimulates vascularization during embryogenesis and in neoplastic tissues (Semenza). 
The VEGF family consists of five members: VEGF-A (referred to here simply as VEGF), VEGF-
B, VEGF-C, VEGF-D, and placental growth factor (PlGF). VEGF exerts its effects on the 
vascular endothelium through binding to several high-affinity receptors, including VEGFR-1 
(also known as FLT-1) and VEGFR-2 (also known as FLK-1 and KDR). The expression of VEGF 
and VEGFR correlates with the grade of diffuse astrocytomas, is crucial for glioma growth, and 
displays a temporal and spatial correlation with the angiogenesis seen in human gliomas. Hypoxia 
induces HIF-1α expression in GBMs and is the main molecular basis for the activation of VEGF 
gene transcription, leading to angiogenesis. The expression level of HIF-1α and VEGF in both 
human and murine gliomas is intense around areas of necrosis in pseudopalisading tumor cells, 
suggesting that this pattern of HIF-1α and VEGF expression is modulated by tumor oxygenation 
(Plate, Breier et al. 1992). 
The molecular switch that is at the basis of vasculogenesis, is largely induced by hypoxic 
conditions and promotes the recruitment of circulating BMDCs (Zagzag, Esencay et al. 2008). 
Although no evidence exists for a direct relationship between hypoxia and vascular mimicry in 
GBMs, Sun et al demonstrated that hypoxia influences vascular mimicry in melanoma models (in 
which vascular mimicry was first described) (Sun, Zhang et al. 2007). 
There are suggestion in GBMs of a tumor-derived endothelial cell population. Tumor-derived 
endothelial cells were not a result of fusion between tumor cells and endothelial cells. Reduced 
oxygen concentration enhanced this morphological change, in fact tumor-derived endothelial cells 
colocalized with hypoxic portions of the tumor, suggesting a role for hypoxia and HIF-1 in the 
transdifferentiation of GBM cells (Soda, Marumoto et al.). 
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1.2.3 Role of Glioma stem cells in Angiogenesis 
 
Some experimental evidence suggests that GSCs play a critical role in tumor progression, at least 
in part, through their promotion of angiogenesis. Furthermore, tumors with a high GSC content 
are highly angiogenic. VEGF and SDF-1α have been shown to be important angiogenic factors 
released by GSC (Folkins, Shaked et al. 2009). 
Folkins et al recently described increased microvessel density and tumor perfusion, as well as 
mobilization and homing of EPCs, in tumors rich in cancer stem cells (CSCs).Thus, the molecular 
mechanisms controlling vasculogenesis and leading to the mobilization and recruitment of EPCs 
and bone marrowderived tumor-associated macrophages to the neovascularization of brain tumors 
have been partially elucidated and appear to be similar, at least in part, to those described for 
angiogenesis (Folkins, Shaked et al. 2009). 
Dong et al demonstrated the incorporation of vascular mimicry in the neovascularization process 
in a xenograft model injected with human GSC-derived tumors. They identified the formation of 
patterned tubular networks by tumor cells mimicking endothelial-lined vascular networks. They 
suggest that cell fusion could be one mechanism by which vascular mimicry occurs (Dong, Zhang 
et al.). 
The close association between endothelial cells and neural stem cells was demonstrated by Shen 
et al, who established that factors secreted by endothelial cells stimulate self-renewal of neural 
stem cells and proposed that endothelial cells are an integral component of the stem cell niche. 
This vascular niche has also been applied to GSCs and is the protective glioma 
microenvironment, in which GSCs are able to freely proliferate and remain undifferentiated, 
completely unaffected by any external influences (Shen, Goderie et al. 2004). Another group have 
demonstrated that a substantial fraction of CD31+ endothelial cells expressed the same 
chromosomal aberrations as were present in tumor cells within the specimen, suggesting that at 
least some endothelial cells originate from the tumor itself (Ricci-Vitiani, Pallini et al.). Cultures 
of GSPCs in transdifferentiation medium resulted in a characteristic flagstone morphology within 
10 days, and culture in Matrigel ultimately produced vessel-like structures, with some cells 
appearing as endotheliocytes. The transdifferentiation process was associated with an increase in 
transcription and expression levels of markers of vascular endothelial cells (Dong, Zhao et al.). 
1.2.4 Vascular Endothelial Growth Factor: the most important pro-angiogenic 
molecule 
 
A large number of pro-angiogenic factors have been identified; perhaps the best characterized is 
vascular endothelial growth factor (VEGF, also known as vascular permeability factor), which is 
relatively unique among growth factors in terms of its specificity for the vascular endothelium. 
This family of structurally related molecules includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
and placental growth factor (PlGF) (Hicklin and Ellis 2005). The major mediator of tumor 
angiogenesis is VEGF-A, usually referred to as VEGF. VEGF signals mainly through VEGF 
receptor 2 (VEGFR-2), which is expressed at elevated levels by endothelial cells engaged in 
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angiogenesis and by circulating bone marrow–derived endothelial progenitor cells. VEGF, the 
most potent direct-acting angiogenic protein known, is a diffusible endothelial cell-specific 
mitogen and angiogenic factor that also increases vascular permeability (Connolly, Heuvelman et 
al. 1989). It elicits a pronounced angiogenic response in a variety of in vivo models. Endothelial 
cell survival in newly formed vessels is VEGF-dependent. VEGF overproduction has been 
identified as a major factor underlying pathological angiogenesis in “in vivo” conditions such as 
psoriasis, macular degeneration, and tumor proliferation (Alon, Hemo et al. 1995). Hypoxia 
appears to be an important stimulus for VEGF production in both malignant and normal cells 
Transcription of VEGF mRNA is also induced by a variety of growth factors and cytokines, 
including PDGF, EGF, tumor necrosis factor alpha, TGF-b1, and interleukin 1-beta. In addition to 
its role in the paracrine stimulation of angiogenesis, VEGF may also have an autocrine 
stimulatory effect on tumor cells (Figure 3). Recent evidence suggests that VEGF may not only 
play a role in inducing angiogenesis but also is important in promoting the survival of new vessels 
formed in tumors. 
 
 
 
 
 
 
 
 
 
 
    
Fig 3.. Paracrine and autocrine stimulation by angiogenic growth factors. From (McMahon 2000) 
 
Three high-affinity cognate endothelial receptors for VEGF have been identified: VEGFR-1/Flt-1, 
VEGFR-2/Flk-1/KDR, and VEGFR-3/Flt-4. These receptors function as signaling molecules 
during vascular development VEGFR-1 and VEGFR-2 are cell surface receptor tyrosine kinases 
(RTKs), which are localized on endothelial cells during embryogenic development. VEGF RTKs 
are single-pass transmembrane receptors that possess intrinsic cytoplasmic enzymatic activity, 
catalyzing the transfer of the gamma-phosphate of ATP to tyrosine residues in protein substrates 
VEGF RTKs, members of a large family of RTKs, are essential components of signal 
transduction pathways that affect cell proliferation, differentiation, migration, and metabolism. 
Activation of VEGF RTKs occurs through ligand binding, which facilitates receptor dimerization 
and autophosphorylation of tyrosine residues in the cytoplasmic portion. The phosphotyrosine 
residues either enhance receptor catalytic activity or provide docking sites for downstream 
signaling proteins VEGFR-2 is exclusively expressed in endothelial cells and appears to play a 
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pivotal role in endothelial cell differentiation and vasculogenesis. Many studies using molecular 
techniques have provided evidence for the role of VEGFR-2 in tumor vascularization, growth, 
and metastasis (Millauer, Wizigmann-Voos et al. 1993). Most types of human cancer cells express 
VEGF, often at elevated levels; this is a likely consequence of the numerous and diverse genetic 
and epigenetic ways in which VEGF can be induced (Kerbel and Folkman 2002). Hypoxia, a 
characteristic of solid tumors, is an important inducer of VEGF. Its effect is mediated through the 
hypoxia-inducible transcription factors 1α and 2α (Semenza 2003). 
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1.3 CURRENT THERAPIES FOR GLIOMAS 
 
The current standard of care consists of surgical resection followed by radiotherapy and 
chemotherapy (Stupp and Roila 2009). However, the effectiveness of surgical resection is often 
compromised due to the lack of a defined tumour margin and a tumour burden located at a close 
proximity to vital anatomical structures in the brain. 
The chemotherapeutic agent are also alchilant agents that damage the DNA directly. The most 
used chemotherapeutic agent for the treatment of gliomas is Temozolomide; it is the alkylating 
drug more tolerable and effective, when combined with radiation therapy in patients with an 
initial glioma is able to significantly prolong the survival rate; patients with glioblastoma treated 
with radiotherapy combined with tmz compared with patients treated with only radiation therapy 
have a median survival of 14.6 months compared to 12.1 months with radiotherapy alone. 
However, this therapy has a low degree of efficiency, in fact there are many patients who after 
treatment undergo a new tumor progression (Butowski, Sneed et al. 2006). 
1.3.1 Anti-angiogenic therapy  
 
Tumors require nutrients and oxygen in order to grow, and new blood vessels provide these 
requirements. GBM cells are characterized by their invasive abilities and striking angiogenic 
potential. The blood vessels formed by tumor cells are structurally and functionally abnormal: the 
blood vessels are leaky and dilated, the endothelial cells exhibit aberrant morphology, the 
pericytes are loosely attached or absent and the basement membrane is incomplete (Durupt, 
Koppers-Lalic et al.). These abnormalities lead to an abnormal tumor microenvironment that is 
characterized by interstitial hypertension, hypoxia and acidosis. The abnormal vasculature 
represents a barrier to the delivery and efficacy of anticancer therapeutic agents. These 
observations suggest that if the structure and function of tumor vessels could be “corrected”, then 
the tumor microenvironment might be normalized, ultimately improving the efficacy of cancer 
treatments. As a key mediator of angiogenesis, VEGF and its receptors are targets for anticancer 
therapies (Ferrara, Gerber et al. 2003), in addition to conventional therapies. Targeting the cells 
that support tumor growth, rather than the actual tumor cells, represents a relatively new approach 
to cancer therapy. This approach is particularly promising because these support cells are 
genetically stable and therefore less likely to develop mutations that will allow them to develop 
drug resistance in a rapid manner.  
A significant challenge for anti-angiogenic therapy is to design combination protocols that can 
counteract the diverse angiogenic stimuli produced by the tumor and its microenvironment. 
VEGF signaling inhibitors have been shown to significantly suppress or delay tumor growth in 
several animal models (Kim, Li et al. 1993) and in clinical trials. The humanized monoclonal anti-
VEGF antibody bevacizumab is the first VEGF-targeting drug approved for use in patients with 
metastatic colorectal cancer (Hurwitz, Fehrenbacher et al. 2004), metastatic breast cancer, lung 
cancer, renal cell carcinoma and glioblastoma multiforme (Chamberlain). 
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VEGF expression is regulated by intrinsic and extrinsic factors. Hypoxia and hypoglycemia are 
major stimulators of VEGF expression (Shweiki, Itin et al. 1992). Factors that can potentiate 
VEGF production and stimulate angiogenesis include tumor necrosis factor and transforming 
growth factor. 
Several approaches have been used to eliminate the hypoxic cells within tumors (Bernhard). 
Anti-angiogenic strategies 
Angiogenesis inhibitors have been divided into two classes: direct and indirect (Relf, LeJeune et 
al. 1997). Direct angiogenesis inhibitors, such as endostatin, target the microvascular ECs, 
preventing their response to various proangiogenic stimuli and thereby enhancing the effects of 
chemotherapy. In contrast, indirect angiogenesis inhibitors interfere with the proangiogenic 
communication between the tumor cells and the endothelial cell compartments. Anti-angiogenic 
therapies act predominantly by blocking the binding of VEGF to its receptor and comprise 
neutralizing antibodies against the ligand or the receptor, soluble receptors, or small molecule 
inhibitors directed against the tyrosine kinase activity of the VEGF receptors. 
Due to the potential of tumor “escape” when specific, indirect anti-angiogenic agents (e.g., anti-
VEGF) are delivered individually, appropriate combination protocols employing these agents are 
required for maximal benefit (Kerbel and Folkman 2002). Abdollahi and co-workers show that 
the treatment of tumor xenografts with a combination of endostatin and with VEGF blockers 
results in an enhanced therapeutic effect, which may be attributed to the endostatin-mediated 
downregulation of many regulators of proangiogenic pathways and suppression of alternative 
angiogenic mechanisms that might be upregulated by VEGF blockade (Abdollahi, Lipson et al. 
2003). 
Here, we focus on several molecules that interfere with the VEGF/VEGFR signaling pathway, 
which have been evaluated in clinical trials for solid tumors. In Table 2, we summarize the 
available treatments and the relative clinical phases and results. 
Indirect anti-angiogenic drugs 
As mentioned previously, Bevacizumab (Avastin) is a humanized neutralizing monoclonal 
antibody that blocks the binding of human VEGF to its receptors. A significant tumor response 
was observed in response to Bevacizumab treatment: the 6-month progression-free survival was 
32% in GBM patients (Vredenburgh, Desjardins et al. 2007). However, glioblastoma appears to 
adapt rapidly to anti-VEGF therapy, resulting in rapid tumor progression without improvement in 
overall survival (Xu, Chen et al.; Norden, Drappatz et al. 2009). 
In recent study demonstrated that anti-VEGF therapies can significantly reduce the vascular 
supply, as demonstrated by a decrease in intratumoral blood flow and a strong reduction of large 
and medium-size blood vessels, however these events were also shown to be accompanied by a 
strong increase in infiltrating tumor cells in adjacent brain parenchyma (Keunen, Johansson et 
al.). Finally, a preclinical study (Lucio-Eterovic, Piao et al. 2009) and a clinical trial (Lorgis, 
Maura et al.) suggest that high doses of bevacizumab could directly enhance the invasiveness of 
human glioblastoma cell lines and that dosages lower than those currently used might improve 
patient outcome.  
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In the endothelial cells of normal animals, VEGF-A treatment results in the upregulation of both 
integrins α1β1 and α2β1. The functional blocking of these integrins impairs angiogenesis in vitro 
and reduces VEGF-A-induced angiogenesis and tumor growth in vivo (Senger, Perruzzi et al. 
2002; Sweeney, DiLullo et al. 2003). αvβ3 integrins are highly expressed by proliferating and 
activated vascular endothelial cells. Therefore, they are a major contributor to the formation of 
vasculature by supporting the migration and survival of endothelial cells (Brooks, Clark et al. 
1994). The blockade of αvβ3 integrins inhibits tumor angiogenesis as well as blood vessel 
formation in in vivo models (Drake, Cheresh et al. 1995; Friedlander, Brooks et al. 1995). 
Consequently, αvβ3 might represent a potential target in anti-angiogenic therapy. Antagonizing 
integrins has generally included the targeting of the receptor binding sites or other nearby sites, 
although new alternative approaches target downstream signaling proteins. 
Cilengitide is a cyclic RGD-peptide inhibitor of αvβ3 and αvβ5 integrins. Blocking αvβ3 integrin 
inhibits blood vessel formation in vivo (Fu, Ponce et al. 2007). In a phase II trial, cilengitide was 
associated with a median survival of 10 months in recurrent glioma patients (Reardon, Fink et al. 
2008). Cilengitide is currently in clinical phase III studies for the treatment of glioblastomas and 
is in phase II studies for the treatment of several other tumor types, including breast cancer, 
squamous cell cancer, non-small cell lung cancer and melanoma (Reardon, Neyns et al.; 
Vermorken, Guigay et al.). 
Other drugs targeting integrins include the following agents: 
Abergrin is a humanized antibody against αvβ3 integrins. It blocks integrin binding to vitronectin 
and fibrinogen, preventing cell adhesion, migration, proliferation and integrin-mediated cell 
signaling (Cai, Wu et al. 2006). 
Volociximab is a chimeric human-mouse monoclonal antibody that binds to α5β1 integrins. It 
induces cell death and prevents capillary tube formation in vitro. In vivo, volociximab exhibits 
anti-tumor and anti-angiogenic effects (Ricart, Tolcher et al. 2008). 
Increased matrix metalloproteinase (MMP) levels are associated with glioma invasion and 
angiogenesis. Marimastat reduces MMP levels in patients with gliomas (Levin, Phuphanich et al. 
2006). Phase II clinical trials evaluating the administration of marimastat in combination with 
temozolomide demonstrated promising results (the progression free survival after six months was 
39%), although further investigation is needed for the associated therapy-induced joint pain 
(Groves, Puduvalli et al. 2002). 
Sorafenib (Nexavar) is a multi-kinase inhibitor of VEGFR2-3, PDGFR, Raf kinase and c-Kit. It is 
currently approved for the treatment of advanced HCC and renal cell carcinoma. Phase II trials 
evaluating the efficacy of sorafenib in patients with malignant glioma are currently ongoing 
(Wong, Prawira et al. 2009). Hypertension is a specific side effects of sorafenib and of most anti-
angiogenic agents due to the decreased production of nitric oxide and prostacyclines in vascular 
endothelial cells (Maitland, Kasza et al. 2009). 
Cediranib (Recentin) is a potent inhibitor of both VEGFR-1 and VEGFR-2. It also exhibits 
activity against c-kit, PDGFR-beta and FLT4. It is well tolerated, and an inverse correlation was 
found between cediranib dose- and time-dependent treatment and soluble VEGFR-2 (Fiedler, 
Mesters et al.). 
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Sunitinib (Sutent) is a multi-kinase inhibitor of VEGFR 1-3, RET and PDGFR, approved for 
treatment of RCC, imatinib-resistant gastrointestinal stromal tumors (GIST) and pancreatic 
neuroendocrine tumors (pNET) (Raymond, Dahan et al.; Demetri, van Oosterom et al. 2006; 
Motzer, Hutson et al. 2007). A recent preclinical study (Matsumoto, Batra et al.) shows that after 
starting sunitinib treatment, there is a period when tumor oxygenation is higher in treated 
compared to untreated mice. The improved oxygenation suggests that the residual blood vessels 
had improved function in terms of delivering oxygen and nutrients. A synergistic delay in tumor 
growth was observed when radiation was applied during the enhanced tumor oxygenation after 4 
days of sunitinib administration. 
Imatinib is a kinase inhibitor of PDGFR, c-kit and bcr-abl. Administration of imatinib at low 
concentrations can act as a cytostatic agent, whereas at high concentrations, it predominantly 
behaves as a cytotoxic agent (Ranza, Mazzini et al.). Imatinib monotherapy has failed due to the 
limited penetration of the drug across the BBB, and for that reason, the inhibition of PDGFR 
alone is insufficient to prevent the growth of malignant gliomas (Wen, Yung et al. 2006).   
Anti-angiogenic therapies are integrated into the treatment strategies for many different tumor 
types. However, not all patients respond to therapy; only a few benefit with progression-free 
survival. In most tumors, anti-angiogenic treatment is combined with chemotherapy. Furthermore, 
a major problem of this therapy is the development of resistance. Extensive evidence indicates 
that anti-angiogenic therapy might actually enhance tumor progression by promoting an invasive 
phenotype that allows for tumor cells to escape angiogenic inhibition. 
The identification of predictive biological markers of objective response will be critical for the 
assessment of the response rates correlated with overall survival and of the development of 
resistance to anti-angiogenic drugs. These markers will provide important indices to aid in the 
improvement of therapeutic efficacy or in the development of alternative anti-angiogenic 
therapies in the event of treatment failure. 
Drug Target Clinical phase Results 
Endostatin 
(Endostar) 
Interfere with the pro-
angiogenic action of 
growth factors 
Phase III    
2005 
Significant and clinical 
improvement in response rate, 
median time to tumor 
progression, and clinical benefit 
rate in combination with 
chemotherapy (Wang, Sun et al. 
2005)  
Bevacizumab 
(Avastin) 
Monoclonal antibody 
anti-VEGF 
Approved in 
2004 
In May 2009, the FDA approved 
Avastin as a single agent for the 
treatment of recurrent GBM 
based on the demonstration of 
objective response rates in two 
single-arm trials: AVF3708g 
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and NCI 06-C-0064E 
Cilengitide Selective inhibitor of αv 
integrins 
Orphan drug 
by European 
Medicines 
Agency in 
2008 
Phase II trial in conjunction with 
chemotherapy and radiation: 
EMD 121974 in 2010 phase II 
trial in recurrent glioblastomas. 
The efficacy of the cilengitide 
alone is modest, but it is 
adequately delivered to the 
tumor (Gilbert, Kuhn et al.). In a 
phase II study, the addition of 
cilengitide to standard chemo-
radiotherapy demonstrated 
promising activity in GBM 
(Stupp, Hegi et al.)  
Etaracizumab 
(Abegrin) 
Humanized Monoclonal 
Antibody Direct Against 
the Human αvβ3 integrin 
Phase II/Phase 
I 
Well tolerated with no evidence 
of immunogenicity (Delbaldo, 
Raymond et al. 2008). Does not 
improve the effect of 
decarbazine in a phase II trial of 
metastatic melanoma (Hersey, 
Sosman et al.)  
Volociximab Chimeric monoclonal 
antibody that binds to and 
inhibits αvβ1 integrin 
Phase II Despite insufficient clinical 
activity in the refractory patient 
population to continue the study, 
weekly volociximab was well 
tolerated. A better understanding 
of the mechanism of action of 
volociximab will inform future 
development efforts (Bell-
McGuinn, Matthews et al.) 
Marimastat  Broad-spectrum matrix 
metalloproteinase 
inhibitor 
Phase III Treatment with marimastat in 
SCLC and GBM patients does 
not improve survival (Shepherd, 
Giaccone et al. 2002; Levin, 
Phuphanich et al. 2006) 
Sorafenib Small molecular inhibitor 
of several tyrosine protein 
kinases (VEGFR and 
PDGFR) and Raf kinases 
Approved in 
2007 for liver 
and kidney 
cancer 
Phase I and II trials for brain 
tumors. Sorafenib can be safely 
administered (Nabors, Supko et 
al.; Reardon, Vredenburgh et 
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al.)  
Cediranib Potent inhibitor of 
VEGFR 
Phase I, Phase 
II 
Modest single agent activity 
(Alberts, Fitch et al.; Garland, 
Chansky et al.). Cediranib 
monotherapy yielded 
encouraging responses in 
recurrent glioblastoma in a 
phase II study (Batchelor, Duda 
et al.)  
Sunitinib Multi-target receptor 
tyrosine kinase inhibitor 
Approved for 
renal cell 
carcinoma and 
for imatinib-
resistant 
gastrointestinal 
stromal tumor 
Single agent sunitinib exhibited 
insufficient activity in patients 
with recurrent glioblastoma in a 
phase II study (Neyns, Sadones 
et al.)  
Imatinib Specific inhibitor of 
receptor tyrosine kinase 
Approved in 
2011 for ten 
different 
cancer types 
In brain tumors, it did not show 
clinically meaningful anti-tumor 
activity in phase II and phase III 
trials (Dresemann, Weller et al.; 
Razis, Selviaridis et al. 2009; 
Reardon, Dresemann et al. 
2009) 
Table 1. Summary of the available treatments and the relative clinical phase and results. 
 
1.3.2 Molecular mechanisms of resistance to anti-angiogenic therapy in glioma  
 
VEGF is ubiquitously expressed in almost all tumors. Tumor cells have been demonstrated to 
secrete VEGF, which leads to increased angiogenesis (Jin, Li et al.; Kamat, Rajoria et al.). 
Although anti-angiogenic treatment yields survival benefits for patients with many different types 
of aggressive tumors, VEGF pathway inhibitors are nonetheless failing to produce enduring 
clinical responses in most patients (Kindler, Niedzwiecki et al.; Saltz, Lenz et al. 2007). 
Alternative pathway activation by tumoral cells 
One way that tumor cells bypass anti-angiogenic therapy is via the activation or upregulation of 
alternative pro-angiogenic pathways. In preclinical models and in clinical trials, overexpression of 
fibroblast growth factor 1 and 2, ephrin and angiopoietin was found in tumors that were treated 
with inhibitors of VEGF signaling (Casanovas, Hicklin et al. 2005).  
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Pericytes play an important role in the pathology of aberrant tumor vasculature. The vessels 
within tumors that survive anti-angiogenic therapy are tightly covered with pericytes, which are 
recruited by vascular endothelial cells to provide VEGF, the most important survival signal for 
endothelial cells (Kamba and McDonald 2007). Important features of hypoxic remodeling include 
the loss of small vessels and extensive proliferation of vascular mural cells (MC) in the surviving 
vasculature. PDGF-B appears to play a significant role in promoting the integrity of vascular 
networks during conditions of environmental stress. Recruited MCs are key contributors to the 
maintenance of tumor neovasculature. PDGF-B signaling via the PDGF receptor-β (PDGFR-β) 
plays a critical role in MC recruitment (Kourembanas, Hannan et al. 1990). Similar to VEGF, 
PDGF-B expression in ECs is critically regulated by oxygen tension, and PDGF-B overexpression 
is associated with abnormal proliferation of MCs (Faller 1999). Members of the ephrin family 
have been shown to play important roles in regulating the assembly of vascular cells. 
However, increased PDGF-B expression has only been found in recurrent xenografts. PDGFR-β 
was also found in the large vessels of the recurrent tumors. Prolonged anti-angiogenic therapy 
significantly alters the expression of angiogenic factors implicated in vascular MC recruitment, 
causing extensive morphological changes in vessels, including significant increases in diameter 
and active proliferation of vascular mural cells (Huang, Soffer et al. 2004). 
Cancer cells can also adapt to the disruption of vessels by extravasating into normal tissues 
(Rubenstein, Kim et al. 2000). 
An alternative mechanism of escaping from VEGF blockade might be attributed to the local 
contribution of VEGF by the host stroma, which is sufficient to maintain persistent vessels and to 
sustain tumor growth. When host-derived VEGF is blocked, tumors exhibit extensive necrosis 
(Glade Bender, Cooney et al. 2004). Breast cancer studies have revealed that mammary stromal 
fibroblasts might produce factors that influence the growth and malignant progression of a tumor 
via paracrine effects on the tumor-associated endothelium (Hlatky, Tsionou et al. 1994). 
The tumor recruits different types of cells 
Tumor hypoxia caused by the loss of functional vasculature after conventional therapy (e.g., 
irradiation) results in the upregulation of VEGF to stimulate vascular proliferation and is the 
stimulus for the influx of BMDCs (bone marrow derived endothelial cells). The two principal 
ways in which a tumor can expand its vasculature as it grows is either by angiogenesis, which 
involves the sprouting of endothelial cells from nearby normal vessels, or by vasculogenesis, 
which occurs by the recruitment of circulating endothelial and other cells into the tumor. Both the 
pharmacological or genetic inhibition of HIF-1alpha attenuates BMDC recruitment and inhibits 
tumor recurrence. Such BMDC accumulation is composed largely of CD11b+ monocytes. These 
cells are highly proangiogenic, suggesting that they are attractive targets for enhancing the 
response of tumors to irradiation (Ruzinova, Schoer et al. 2003; Bailey, Willenbring et al. 2006). 
In addition, CD11b+Gr-1+ cells (also defined as myeloid-derived suppressor cells, MDSC) have 
been found to be frequently increased in tumors and to mediate their resistance to anti-VEGF 
treatments by producing several angiogenic factors including G-CSF and Bv8 (Shojaei, Wu et al. 
2007).  
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Other cells are important for tumor growth and angiogenesis. For instance, there is an inverse 
relationship between macrophage density and vascular density (Leek, Lewis et al. 1996). Hypoxia 
upregulates the production of pro-angiogenic growth factors and cytokines by tumor-associated 
macrophages (TAM) (Lewis and Pollard 2006). Macrophage infiltration was demonstrated to be a 
prerequisite step for the angiogenic switch, which correlates with the transition to a malignant 
tumor phenotype (Lin, Nguyen et al. 2001). TAMs secrete a number of mitogenic cytokines and 
growth factors, which are involved in a range of paracrine loops that promote tumor cell 
proliferation and growth. A number of studies have shown that TAM infiltration correlates with 
increased cell proliferation growth of many tumors (Bingle, Brown et al. 2002). The indirect role 
of TAMs in angiogenesis is also essential for tumor growth, as they provide oxygen and nutrients. 
Microglia and macrophages can be recruited either by resident brain microglia or by activated 
perivascular macrophages. Microglia are recruited to the glioma, where they can produce 
cytokines to benefit glioma cell proliferation and migration. The cytokines produced include 
MCP-1 (monocyte chemoattractant protein-1) (Platten, Kretz et al. 2003), G-CSF (Granulocyte 
colony stimulating factor) (Mueller and Fusenig 1999), and several growth factors such as EGF, 
VEGF, HGF and SCF (Briers, Desmaretz et al. 1994; Lafuente, Adan et al. 1999). HGF and its 
receptor are expressed in both microglia and glioma and stimulates angiogenesis, metastasis and 
proliferation (Zhang, Himi et al. 2000; Kunkel, Muller et al. 2001). Upregulation of TGFβ might 
be involved in promoting tumor proliferation and invasion, whereas TNFα is mainly produced by 
microglia because it has been found to be overexpressed in human glioma but not in isolated 
glioma cell lines (Hao, Parney et al. 2002). 
Initially, infiltration of microglia has been proposed to defend the brain parenchyma against tumor 
cells (Galarneau, Villeneuve et al. 2007). However, microglia can interact with the tumor 
environment and, when activated by the glioma, secrete factors including MMPs that degrade the 
ECM. Thus, utilizing this strategy, glioma cells can invade and expand into the brain parenchyma 
(Ghosh and Chaudhuri).  
Some characteristics of macrophages/microglia are also exhibited by tumor cells. The phagocytic 
activities observed in human GBM are properties of malignant macrophages/microglia (Persson 
and Englund 2009). Subpopulations of neoplastic GBM cells exhibit the phagocytic behavior of 
macrophages/microglia. Notably, GBM tumors contain cells that are positive for both the 
phagocytic macrophage/microglia marker CD68 and tumor markers such as hTERT. As microglia 
are the resident macrophages of the brain, subpopulations of the malignant GBM cells could also 
arise from microglia/macrophages (Seyfried, Kiebish et al.). 
Myeloid cells have been observed to fuse with tumor cells, producing daughter cells endowed 
with the invasive properties of myeloid cells and the unlimited proliferative potential of tumor 
cells (reviewed in (Rachkovsky, Sodi et al. 1998)). More recently, Pawelek et al. demonstrated 
that the fusion between non-metastatic cells and macrophages can result in cells with the ability to 
invade and metastasize (Pawelek and Chakraborty 2008). Macrophage/microglial antigens are 
expressed on neoplastic cells within GBM (Strojnik, Kavalar et al. 2006). It is possible that 
macrophages fuse with tumor cells during attempts to engulf the cells but that the resulting fusion 
produces more aggressive and invasive tumor cells (Shabo, Olsson et al. 2009). 
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VEGF blockade might be more effective if combined with therapies that also damage endothelial 
cells. Because endothelial cells proliferate at a slower rate than tumor cells, after the 
administration of a low-dose cytotoxic therapy, normal endothelial cells might be able to survive 
during the recovery period (Browder, Butterfield et al. 2000).  
Anti-VEGF treatment suppresses the vasculature but not the co-opted vessels (Kioi, Vogel et al.). 
Electron microscopic analysis of capillary formation has found that the complex vascular 
structures within tumors are composed essentially of progenitor endothelial cells. Cells with 
ultrastructural features of endothelial progenitors are recruited to the tumor periphery prior to 
vessel formation. Endothelial progenitors are migratory endothelial cells with characteristic 
ultrastructural features and the capacity to circulate, proliferate and differentiate into mature 
endothelial cells (Frontczak-Baniewicz, Czajkowska et al. 2008). 
Vascular endothelial cells might also represent a target for cytotoxic therapy, as they might be 
capable of resuming growth during the recovery period after the cytotoxic treatment. However, 
Browder et al. hypothesized that endothelial cell recovery occurring during this treatment-free 
period might support the regrowth of tumor cells. This could increase the risk of the emergence of 
drug-resistant tumor cells (Browder, Butterfield et al. 2000). Considering that chemotherapeutic 
agents themselves can elicit anti-angiogenic effects, dosing schedules must be carefully designed 
to induce maximal apoptosis of the endothelial cells. Some chemotherapeutic agents, in particular, 
exhibit maximal benefit when administered at a low-dose for long treatment periods (metronomic 
therapy). The same group has conducted a clinical trial in which children with recurrent or 
progressive cancers were treated with low-dose chemotherapy in combination with anti-
angiogenic therapy. Forty percent of patients exhibited prolonged or persistent disease-free status 
for all of the six months of therapy (Kieran, Turner et al. 2005). 
Recent studies suggest that tumor cells can also be involved in tumor angiogenesis, as neoplastic 
lesions have been found to contain tumor-derived endothelial cells (TDECs). These cells originate 
from the tumor-initiating cells but not from EC progenitor cells. Through the activation of HIF-
1alpha, hypoxia plays an important role in endothelial differentiation. This switch is independent 
of VEGF or FGF. In this model, the VEGF inhibitor treatment elicited no effects on tumor growth 
(Soda, Marumoto et al.).   
Tumors can adapt to treatment with angiogenesis inhibitors by activating alternative 
angiogenesis-promoting mechanisms to sustain tumor growth (Fernando, Koch et al. 2008).  
In clinical trials evaluating bevacizumab, sorafenib and sunitinib, a minority of individuals failed 
to show even transitory clinical benefit (Batchelor, Sorensen et al. 2007). In these cases, the 
tumors exhibited pre-existing resistance, which was attributed to the activation of one or more of 
the aforementioned evasive resistance mechanisms, not in response to therapy but to the selective 
pressure of their microenvironment. Thus, it is important to identify markers of resistance and to 
identify new approaches for targeting angiogenesis. 
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1.4 THE IMPORTANCE OF INTEGRIN LINKED KINASE 1 
ILK1 is a 59 kDa cytoplasmic protein that contains three distinct domains: (a) an N-terminal 
ankyrin repeat domain that facilitates protein interactions and (b) a phosphoinositide 
phospholipid-binding domain that mediates phosphoinositide binding, (c) a C-terminal 
serine/threonine protein kinase domain. 
  
Fig 5.. Schematic of ILK-1 primary structure. The three conserved functional domains of integrin-linked kinase (ILK) are 
represented. Four amino-terminal ankyrin repeats (blue) mediate protein interactions that serve to localize ILK to focal adhesions 
and also regulate ILK signalling. The pleckstrin homology domain is indicated in yellow, and boxed residues above the sequence 
highlight conserved amino-acid residues, some of which are required for phosphoinositide binding. Boxed residues below the 
catalytic domain (green) indicate two non-conserved amino-acid motifs (PRH and SMAD) that align with the conserved HRD and 
DFG triplets, respectively, found in typical kinase domains. From  
 
ILK1 is a serine/threonine kinase that was first discovered as an integrin-binding protein in a 
yeast two-hybrid screen. It is able to directly activate several signaling pathways downstream of 
integrins and to participate in integrin signaling crosstalk with growth factors and hormones. 
Substrates of the ILK1 include integrin β1 (2), myosin light chain (MLC) (5), protein kinase B 
/Akt (AKT) and Glycogen synthase kinase 3 (GSK-3) (6). ILK1 is a unique kinase because it also 
functions as an intracellular adaptor protein, coupling a wide variety of signaling proteins to 
integrin and growth factor signaling. ILK interacting proteins include Pinch (7), Paxillin (8), 
Parvins (9), Affixin (10), ILK BP (11), p21 activated kinase 1 (Pak1) (12) and estrogen receptor 
(ER) (13). Physiological signals including growth factors (6), cytokines (14, 15) estrogen (16), 
and the Wnt pathway (17) can activate ILK. Direct regulators of ILK include phosphoinositide 3-
kinase (PI3K) (6), phosphatase and tensin homolog (PTEN) (18), protein phosphatase 2C (19), 
ILKAP (20) and secreted protein acidic and rich in cysteine (SPARC) (21). ILK is implicated in 
the regulation of anchorage-dependent cell growth and survival, cell-cycle progression7,10, 
Epithelia-Mesenchimal Transition (EMT), invasion and migration11, cell motility and 
contraction12, vascular development13,14, and tumour angiogenesis15,16. Cell proliferation can 
be modulated by cooperative interactions between growth factor receptor-induced pathways and 
integrin signaling. These different roles of ILK result from its combined functions as an adaptor 
protein and its kinase-associated activity.  
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1.4.1 ILK-1 signalling and tumorigenesis 
 
ILK-1 signaling axis is implicated in many key signaling pathways that are activated in tumour 
cells promoting anchorage independence, motility, apoptosis, angiogenesis, EMT and tumor 
progression (22). Overexpression of ILK-1 in epithelial cells enables anchorage independent 
growth and survival of tumor cells (22–24) and tumorigenicity in nude mice 25 Soon after the 
discovery of ILK, it became clear that overexpression of active ILK in epithelial cells resulted in 
the transformation of the cells into anchorage-independent, highly migratory, invasive cells with 
mesenchymal properties. Many of these oncogenic properties of human cancer cell lines can be 
suppressed by inhibiting ILK activity or expression, indicating that ILK could be an important 
therapeutic target in cancer. Increased ILK expression was shown to stimulate the expression and 
activity of the matrix metalloproteinase. Accumulating evidence implicates ILK1 as a potential 
oncogene modulating several signaling pathways for cancer cell survival and tumor progression 
(22). Evidence also implicates ILK1 in regulating tumor angiogenesis; ILK1 increases vascular 
endothelial growth factor (VEGF), modulate levels of hypoxia inducible factor (HIF1α) and 
promote cell migration, blood-vessel formation and tumor growth of VEGF-treated endothelial 
cells (35, 36). ILK1 promotes epithelial to mesenchymal transformation (EMT) of cancer cells by 
modulating β -catenin/TCF, Snail and TGFβ  pathways (38–40). these evolving findings indicate 
ILK1 signaling has the potential to activate multiple signaling pathways that contribute to the 
growth advantage of cancer cells. ILK-mediated EMT is accompanied by increased migration and 
invasion105. Increased ILK expression was shown to stimulate the expression and activity of the 
matrix metalloproteinase MMP9, through activation of AP1 transcription factor110 (FIG. 3). 
Inhibition of ILK activity in highly invasive human glioblastoma cells, and in ILK-overexpressing 
SCp2 mammary epithelial cells, resulted in substantial inhibition of invasion into matrigel, and 
pharmacological inhibition of MMP9 activity also inhibited invasion110, demonstrating that ILK 
can promote invasion through upregulation and activation of MMP9. Inhibiting ILK activity or 
expression also inhibits cell migration43 
1.4.2 Role in angiogenesis 
 
Recent studies have implicated a significant role of ILK in vascular development, vascular 
morphogenesis and tumour angiogenesis. Endothelial-cell-targeted knockout of ILK results in 
embryonic lethality with severe defects in placental and embryonic vascularization14. ILK was 
shown to regulate vascular network formation by directing the assembly of integrin-dependent 
matrix-forming adhesions13. ILK also has an important role in regulating tumour angiogenesis. 
ILK-overexpressing cells were found to express high levels of vascular endothelial growth factor 
(VEGF). ILK seems to be a crucial component of the constitutively activated PI3K pathway in 
these cells, which controls the expression of VEGF through AKT, mammalian target of 
rapamycin (mTOR) and hypoxia-inducible factor-1α (HIF1α). Collectively, these studies 
demonstrate a crucial role of ILK in the regulation of vascular morphogenesis. Recent findings in 
a number of cancers indicate that ILK expression is increased in tumours, and that, in general, 
higher-grade tumours express higher levels of ILK protein, this has been demonstrated in different 
kind of cancer: prostate cancer, human colon adenocarcinoma, gastric cancers, ovarian cancers, in 
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malignant melanomas. These findings that ILK protein levels are increased in several types of 
cancer indicate that ILK gene transcription, translation or protein stability could be dysregulated 
in cancer cells. The constitutively high levels of ILK expression and activity in cancer cells 
compared with the surrounding normal cells, offers a therapeutic window for downregulating ILK 
activity in the cancer cells to the level of the normal cells.  
An interesting recent finding indicates that tumours expressing high levels of constitutively 
activated ILK are more sensitive to radiation-induced cell death128, suggesting that tumours with 
increased ILK expression or hyperactive ILK might benefit from radiation treatment. An 
important point when considering ILK as a therapeutic target is that inhibiting ILK activity slows 
down tumour progression and is cytostatic rather than cytotoxic. As with other potential 
therapeutics of this ilk, such as anti-angiogenic compounds, anti-ILK therapeutics will probably 
be most effective when combined with low-dose cytotoxic agents or other compounds acting on 
parallel signalling pathways. 
1.4.3 Our interest in ILK 
 
In our lab we are interested to understand the escape of the tumour to the anti-angiogenic therapy. 
We treated the mice injected with human tumoral cells with anti-angiogenic compound: PF4-DLR 
that has been demonstrated to have a strong anti-angiogenic activity (lavoro di andreas).After 10 
days of treatment we saw that the gliomas are fully responsive to PF4-DLR treatment, while they 
start to become unresponsive at 20 days. With a proteomic approach, we identified different 
proteins that have e different expression profile after 10 or 20 days of treatment. Among the 
identified proteins we decided to concentrate our attention on ILK. Overexpression of ILK in 
tumorigenic cells induces the acquisition of an invasive phenotype, and cell transformation.  (fare 
un riferimento ai lavori che ho citato prima). At 10 days tumor grown is mostly inhibited by PF4-
DLR and ILK expression is low, at 20 days glioma are resistant to PF4-DLR treatment and ILK 
expression is high. Furthermore ILK expression is higher compare to untreated gliomas, thus 
suggesting that the increased expression of ILK is specifically induced by PF4-DLR treatment.  
These results indicate that ILK is strongly and statistically associated with poor prognosis in 
human gliomas and can represent a new molecular target for patient therapy. We therefore 
decided to inhibit ILK1 using siRNA in addition to PF4-DLR administration in order to 
investigate whether this will further improve therapeutic efficacy in vivo over PF4-DLR alone. 
We then tested whether the inhibitory activity of PF4-DLR can be increased in vivo by combined 
treatment with PF4-DLR and ILK1 siRNA in the experimental glioma model in mice. A first 
osmotic mini-pump releasing PF4-DLR (0.5 mg/kg/day) was implanted 12 days after tumor 
injection, and followed, after additional ten days, by the implantation of a second minipump, 
intrathecally connected, releasing ILK1 siRNA (0.4 mg/day). Animals were sacrificed 10 days 
later. As control, some mice were left untreated and others were treated with PF4-DLR alone for 
20 days. The effect of PF4- DLR and ILK1 siRNA on tumor angiogenesis was also evaluated by 
staining with anti-CD31 antibody. PF4-DLR alone significantly reduced the number of vessels, 
but the reduction was even greater after the combined treatment. 
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We measured ILK1 expression in human glioblastomas (GBM), astrocytomas and 
oligodendrogliomas by immunoblotting. We also correlated ILK1 expression levels of tumors to 
the time of recurrence (NR: long-term recurrence, more than one year after initial treatment, R: 
short-term recurrence, less than four months after initial treatment). ILK1 was significantly more 
expressed in the subset of patients with early recurrence in all three types of glioma. This suggests 
that gliomas expressing high ILK1 levels are more aggressive. 
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2 AIM OF THE WORK 
 
Glioblastoma multiforme (GBM, WHO grade IV) is the most frequent malignant tumour of the 
central nervous system (CNS) representing up to 50% of all primary brain gliomas, accounts for 
approximately 12-15% of all brain tumors and is one of the most lethal cancers in adults and 
children; the prognosis of patients with GBM remains poor (Ohgaki, Dessen et al. 2004). Despite 
aggressive treatments with surgery, radiation, and chemotherapy, median survival is less than 15 
months and overall survival is less than 10% at 5 years. The treatment difficulty is due to the 
exceptionally infiltrative nature of GBM and its proclivity to integrate into normal brain tissue. To 
date, the management of patients with GBM continues to harbor significant challenges, and 
comprehensive genetic screens of tumor tissues and signaling pathways have been explored to 
develop molecular based targeted therapies. GBM cells are characterized by their invasive 
abilities and striking angiogenic potential. The blood vessels formed by tumor cells are 
structurally and functionally abnormal: the blood vessels are leaky and dilated, the endothelial 
cells exhibit aberrant morphology, the pericytes are loosely attached or absent and the basement 
membrane is incomplete (Durupt, Koppers-Lalic et al.). These abnormalities lead to an abnormal 
tumor microenvironment that is characterized by interstitial hypertension, hypoxia and acidosis. 
The abnormal vasculature represents a barrier to the delivery and efficacy of anticancer 
therapeutic agents. These observations suggest that if the structure and function of tumor vessels 
could be “corrected”, then the tumor microenvironment might be normalized, ultimately 
improving the efficacy of cancer treatments. As a key mediator of angiogenesis, VEGF and its 
receptors are targets for anticancer therapies (Ferrara, Gerber et al. 2003), in addition to 
conventional therapies. Targeting the cells that support tumor growth, rather than the actual tumor 
cells, represents a relatively new approach to cancer therapy 
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3 MATERIALS AND METHODS 
 
3.1 CELL CULTURES AND REAGENTS 
 
3.1.1 Cells cultures 
 
The human glioma cell line U87-MG (American Type Culture Collection, Manassas, VA) was 
used in in vitro and in the animal experiments. The cells were cultured in aMEM (Life 
Technologies, Inc., Grand Island, NY) supplemented with 2 mM L-glutamine, 10% FBS, and 
1000 units/ml gentamycin solution, maintained in T-25 tissue culture flasks in 5% CO2/95% air at 
37 ºC in a humidified incubator. For the implantation experiments, U87-MG cells were dispersed 
with a 0.05% solution of trypsin/EDTA (Life Technologies), reaction was stopped with FBS. The 
cells were washed with PBS, and adjusted to a final concentration of 1*106 cells/100 µl in PBS. 
Bovine Corneal Endothelial cells (BCE, LGC Standard) were used in in vitro experiments. The 
cells were cultured in DMEM low glucose (Life Technologies, Inc., Grand Island, NY) 
supplemented with 1 mM L-glutamine, 10% FBS, 1000 units/ml gentamycin solution and 1 
ng/mg FGF, maintained in T-25 tissue culture flasks in 5% CO2/95% air at 37 ºC in a humidified 
incubator. 
3.1.2 Reagents 
 
Sunitinib ® 
Dissolved in DMSO at the concentration of 250 mg/ml, diluted at the concentration of 10 mg/ml 
in acetate buffer (pH 4.6) and given per os 40mg/Kg/die for the in vivo studies; dissolved in 
DMSO at the concentration of 10 mM for in vitro studies and given to the cells at three different 
concentration: 2,5 µM, 5 µM and 10 µM. 
 
Molecular structure of Sunitinib 
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Sorafenib ® 
Dissolved in DMSO at the concentration of 250 mg/ml, diluted at the concentration of 10 mg/ml 
in acetate buffer (pH 4.6) and given per os 50mg/Kg/die for the in vivo studies; dissolved in 
DMSO at the concentration of 100 mM for in vitro studies and given to the cells at three different 
concentration: 2,5 µM, 5 µM and 10 µM. 
 
Molecular structure of Sorafenib 
QLT0267 
QLT0267 (QLT Inc, Vancouver BC, Canada) was dissolved in (PEG300 66%, Tween 80 8.2%, 
Ethanol 95% 25%, citric acid 0.2%) for in vivo studies and given per os 100mg/Kg/die  
 
Molecular structure of ILK-1 inhibitors member of pharmacor family 
 
3.2 TREATMENTS 
 
 3.2.1 Treatments for protein extraction 
 
U87 cells were plated into 12 multiwell (Euroclone) in a density of 120000 cells/well. The day 
after were treated with anti-angiogenic drugs (at the concentration of 2,5 µM, 5 µM and 10 µM) 
alone or in combination with QLT0267 (at the concentration of 100 µM), the control cells 
received only medium. After 6 hours all the cells were collected in sample buffer, boiled 5 
minutes and analyzed by SDS-PAGE.  
3.2.2 treatments for MTS test  
 
U87 cells and BCE cells were plated into 96 multiwell (Euroclone) in a density of 5000 cells/well. 
The day after were treated with anti-angiogenic drugs (at the concentration of 2,5 µM, 5 µM and 
10 µM) alone or in combination with QLT0267 (at the concentration of 100 µM), the control cells 
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received only medium, and some cells received the vehicle (DMSO). After six hours, 12 hours, 24 
hours and 48 hours, we change the medium and we put complete medium plus 20 μl of MTS 
reagent (CellTiter 96® Promega), we read the plates at 490 nm 
3.3 SDS-PAGE, WESTERN BLOT ANALYSIS 
 
Proteins were separated in 10% SDS-PAGE and electroblotted onto nitrocellulose membranes in 
buffer containing 0.025 M Tris-HCl, 0.192 M glycine, 20% methanol, pH 8.3 at 240 mA for 120 
min. The reactions were performed by incubating with primary antibodies (RT, 2-3h in 4% milk): 
- rabbit abs anti ILK-1 (1:1000 cell signaling), p-AKT (1:1000 cell signaling), HIF-1α (1:500 
Santa Cruz Biothecnologies), - mouse abs anti Tubulin (1:1000 Sigma Aldrich), pamAKT (1:500 
cell signaling). Horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies 
(1:4000 Jackson) were used as secondary antibodies (RT, 1h in 4% milk). Immunoreactive bands 
were visualized by enhanced chemiluminescence (ECL, GE Healthcare). 
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4 RESULTS 
 
4.1 INHIBITION OF ILK-1 
 
We believe that the synergism of angiogenesis inhibitors with ILK1 inhibitors should be tested 
using small molecular inhibitors blocking ILK1 function and not siRNA. Synthetic siRNA are 
extremely expensive and not likely to be used for systemic administration in the clinic.  
4.1.1 In vitro characterization of QLT0267 
 
We have studied in vitro the efficacy of the ILK-1 inhibitor QLT0267. First, we have analyzed the 
tossicity of QLT0267, for this we have measured the viability of the cells after treatment with a 
MTS assay. We have treated in four different time point: 2 hours, 4 hours, 6 hours, 12 hours and 
24 hours. We found that the tumour cells are almost insensitive to the drug in the first 6 hours, 
after they start to die (Fig 1A). We have looked at the activity of QLT0267 measuring the activity 
of ILK-1 (Fig 1B). The immunoblot for pAKT shows that the drug is active also at 2h of 
treatment and remain active until 6h of treatment. We didn’t measured the activity at 12 and 24 
hours because the U87 cells were dying. The immunoblot for ILK shows that the inhibitor of the 
kinase didn’t change its expression level. 
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Fig 1 effect of the inhibitor of ILK-1 QLT0267 on U87 cells. (A) Viability of  U87 cells at 2h, 4h, 6h, 12h and 24h 
after QLT0267 treatment with MTS assay (** p<0.01); (B) effect of QLT0267 on the activity of ILK-1 in U87 cells 
at 2h, 4h and 6h of treatment. 
4.2 THE COMBINATION OF ANTI-ANGIOGENIC DRUGS AND 
INHIBITION OF ILK-1  
 
4.2.1 The combination of anti-angiogenic drugs and QLT0267 decreases the viability 
of tumoral cells and endothelial cells in vitro 
 
Since we have demonstrated that the silencing for ILK1 increases the efficacy of anti-angiogenic 
treatment in vivo, we have treated human tumoral cells U87 and Bovine Corneal Endothelial 
(BCE) cells with two different anti-angiogenic drugs: sorafenib and sunitinib alone or with the 
concomitant treatment with the ILK-1 inhibitor QLT0267. We have measured the viability of the 
cells by MTS assay at 6 hours of treatment (Fig 2).  
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Fig 2 effect of concomitant treatment with anti-angiogenic drugs and the ILK-1 inhibitor on viability of 
tumoral cells and endothelial cells. (A) MTS assay on human tumoral U87 cells after treatment for 6h with 
sorafenib alone or sunitinib alone (at the concentration of 2,5uM, 5uM and 10uM) and the anti-angiogenic drugs at 
the same concentration plus QLT0267 100uM. (B) MTS assay on  endothelial BCE cells after treatment for 6h with 
sorafenib alone or sunitinib alone (at the concentration of 2,5uM, 5uM and 10uM) and the anti-angiogenic drugs at 
the same concentration plus QLT0267 100uM.  
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The human tumoral cells are more sensitive to the concomitant treatment with both sorafenib and 
sunitinib plus QLT0267, in fact the combination of drugs plus the inhibitor decrease the viability 
to 50% (Fig 2A). On the endothelial cells, the maximum concentration of the anti-angiogenic 
drugs decrease the viability of the cells of 20% for sorafenib and of 40% for sunitinib. The 
addition of QLT didn’t change the viability of the cells and seems to protect them from the anti-
angiogenic drugs (Fig 2B). 
4.2.2 The combination of anti-angiogenic drugs and QLT0267 in vivo reduces tumour 
growth 
 
We then tested the combination of anti-angiogenic drugs and QLT0267 in vivo using a 
subcutaneous model of glioblastoma (Fig 3). 
 
 
 Fig 3 Scheme of in vivo experiment 
 
We divided the animals into six groups with seven animal for each group. We injected 1*106  
human tumoral U87 cells resuspended in PBS into the right flanck of the mice. After 14 days, 
when the tumours were visible, we started the treatment. All the groups were treated per os every 
day for 21 days. The control group was treated with vehicle (PEG300 66%, Tween 80 8.2%, 
Ethanol 95% 25%, citric acid 0.2%, acetate buffer); the other groups were treated with sorafenib 
alone at the concentration of 50 mg/kg/die, with only sunitinib at the concentration of 40 
mg/kg/day and with only QLT0267 at the concentration of 100 mg/kg/day. Finally the remaing 
two groups were treated with the combination of the two drugs, sorafenib plus QLT0267 and 
sunitinib plus QLT0267, at the same concentration. After 21 days we sacrificed the animals and 
we collected the tumours. We then analyzed the volume of the tumours (Fig 4 B). The tumour 
treated with sorafenib showed a worst outcome respect to the tumours treated with sunitinib; in 
fact sunitinib administration lead to the reduction of tumour volume of almost 70% respect to the 
control group. The results given by sorafenib were unexpected because, despite we had an 
average reduction of 30% of tumour volume respect to the control, we noticed a big variability 
amoung the group.  The QLT alone is able to reduce tumour mass, but the combination of both 
sunitinib both QLT0267 had the best outcome, in fact we had a 95% of volume reduction in this 
group. Finally the treatment with sorafenib plus QLT0267 gave a reduction comparable to 
QLT0267 alone (82%) of control. 
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Fig 4 Analysis of tumour volume.  Representative picture of three different tumour collected from mice (A). Graph 
of tumour volume (B). 
4.2.3 The combination therapy decreases the number of vessel 
 
We then looked at the tumor vessel formation. For this purpose, the collected tumors were cut at 
cryostat and stained by immunofluorescence with an antibody that recognizes the murine CD31, a 
marker of vessels (Fig 5). Also in this case we found that the treatment with the combination of 
the two drugs was able to induce the greater reductions in vessel density, 52% reduction in the 
treatment with sunitinib plus QLT0267 and 46% reduction in the treatment with sorafenib plus 
QLT0267 (Fig 5B). 
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Fig 5 Analysis of vessels density (A) Immunofluorescence of 10uM thick slices cutted at cryostat and stained with 
antibody against murine CD31 (red) and DAPI (blue), (B) graph representing the quantification of vessel/area. 
 
 
4.3 EXPRESSION LEVELS OF ILK-1 AND ITS PATHWAY   
 
We then investigated the expression levels of ILK-1 in toumoral samples and the activity of the 
kinase looking at the level of its downstream target: phosphorylated AKT.   
 
4.3.1 The combination of anti-angiogenic drugs and QLT0267 decreases the 
expression level of ILK-1 in vivo 
 
We have measured the expression level of ILK-1 protein through both immunoblotting of tissue 
tumour samples (Fig 6A) and immunofluorescence on slices of tumour samples (Fig 6B). In each 
case we found a strong decrease of ILK-1 expression. The data show that QLT0267 treatment 
decrease the ILK-1 expression of 20% respect to the control group. The greatest decrease can be 
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found in the combination treatment with Sunitinib plus QLT0267, where we found a reduction of 
almost 58% respect to the controls (Fig 6C). 
 
  
 
 
 
Fig 6 Expression level of ILK-1 in tumour sample A) western blot analysis of the expression level of ILK-1 and 
tubulin in tumour lysates and quantification of normalized intensity C). B) immunofluorescence of ILK expression in 
slices from tumoural sample (in green), in red the staining with the antibody against murine CD31, in blue the DAPI. 
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4.3.2 The combination of anti-angiogenic drugs and QLT0267 decreases the activity of 
of ILK-1 in vivo 
 
Since we also found that the QLT0267 is an inhibitor of the activity of ILK-1 but didn’t inhibit its 
expression (see Fig.1), we looked at the activity of ILK-1 measuring the phosphorylation level of its 
major target AKT. Data showed that the combination therapy sunitinib plus QLT0267 decrease the 
phosphorilation of AKT of almost 50% of the control group; this data are in agreement with our 
previous results, in fact we have demonstrated that the silencing of ILK-1 increase the efficacy of 
anti-angiogenic treatment. 
 
4.4 MOLECULAR MECHANISMS OF ILK-1 ACTIVITY 
 
We wanted to better understand the mechanisms underlining the efficacy of combination therapy 
at a molecular level. Since we knew that the pathway ILK-1 - pAKT inhibits the degradation of 
HIF-1α, an important transcription factor involved in angiogenesis and epithelial mesenchimal 
transition, and that this results in an increase of the expression level of HIF-1α, we investigated if 
in our models we had changes in HIF-1α expression. 
 
4.4.1 The combination of anti-angiogenic drugs and QLT0267 decrease the expression 
of HIF-1α  
 
We treated human U87 glioma cells with sunitinib, sorafenib or QLT0267 at the maximum 
concentration that we previously used in vitro alone and with the combination of the two drugs: 
sunitinib plus QLT0267 and sorafenib plus QLT0267. After six hours of treatment, we lysate the 
cells and we looked at the levels of HIF-1α (Fig 7). The immunoblot shows that there is a strong 
decrease of HIF-1α after the combination of the two treatment. 
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Fig 8 Level of HIF-1α expression. The immunoblot swoes the expression level of HIF-1α after treatment of human 
glioma U87 cells with anti-angiogenic drugs and QLT0267. 
We had also checked the level of both ILK-1 and phosphorilated AKT on human glioma cells 
treated for six hours and, in our model, we see a trend of decrease of pAKT in cells treated with 
QLT0267 alone or in combination with both the antiangiogenic drugs, in contrast we didn’t see 
any differences in the expression levels of ILK-1. These are preliminary data and we need to 
increase the number of experiments to be sure that this trend is significant. 
 
 
Fig 9 Level of pAKT and ILK expression The immunoblot swoes the expression level of ILK-1 and pAKT after 
treatment of human glioma U87 cells with anti-angiogenic drugs and QLT0267. 
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5 DISCUSSION 
 
Integrin Linked Kinase 1 (ILK), an intracellular serine/threonine kinase, is implicated in cell 
growth and survival, cell-cycle progression, tumor angiogenesis, and cell apoptosis. This kinase 
had long been studied for its involvement in cancer, since a lot of studies showed that the 
expression and activity of ILK increased significantly in many types of solid tumors. However, 
the exact molecular mechanism of ILK underlie tumor has not been fully ascertained. This kinase 
is a downstream substrate of phosphoinositide 3-kinase (PI3K), and an important upstream kinase 
for the regulation of protein kinase B (PKB/Akt) and GSK3 (Maydan, McDonald et al.). ILK 
kinase activity is stimulated by cellular attachment to extracellular matrix components. These 
stimuli result in suppression of apoptosis and promotion of cell survival via protein kinase B/Akt 
signaling events. Akt is involved in several processes thought to be critical in carcinogenesis, 
including aberrant cell proliferation, evasion from apoptosis, promotion of angiogenesis and 
tumor cell invasiveness Papachristou	  DJ	  ????	  	  	  
ILK expression and activity are increased in many types of cancer, such as prostate, colon, gastric 
and ovarian cancers, malignant melanomas, malignant pleural mesothelioma and NSCLC, bladder 
cancer and breast cancer (Cortez, Nair et al.; Gao, Zhu et al.; Hannigan, Troussard et al. 2005; 
Okamura, Yamaji et al. 2007) 
One of the earliest insights into the potential of ILK1 to govern the metastatic phenotype came 
from the Dedhar lab. They demonstrated that stable overexpression of ILK1 in a murine 
mammary gland epithelial cell lines induced the classic EMT phenotype (Novak, Hsu et al. 1998). 
A feedback mechanism between ILK and VEGF expression was also observed and therefore 
treatment with ILK-1 inhibitor causes a ‘double jeopardy’ situation in the cells by causing 
inhibition of tumorigenesis and suppressing angiogenesis (Tan, Cruet-Hennequart et al. 2004). 
In a melanoma model, Wong and coworkers have shown that ILK expression increases as 
melanoma progresses, they also reported that ILK knockdown impeded melanoma cell migration 
and invasion in vitro (Wong, Ng et al. 2007). Moreover, ILK knockdown significantly impaired 
the growth of melanoma xenografts in severe combined immunodeficient mice, indicating that 
ILK is critically important for melanoma tumor growth (Wong, Ng et al. 2007). ILK 
overexpression in melanoma cells enhances the formation of supportive vasculature in vivo which 
is one of the most important steps in the multistage progression of this aggressive malignancy. 
In breast cancer cells, inhibition of ILK1 activity results in a decrease in AKT Ser473 
phosphorylation and induction of apoptosis (Cortez, Nair et al.). 
We have previously demonstrated the importance of ILK-1 in glioblastoma  
ILK1 targeted treatment using specific ILK1 inhibitors may therefore have potential to reduce 
side effects in cancer patients. Since there are strong evidence that AKT signaling plays an 
important role in the development of hormonal therapy resistance in breast cancer (Tokunaga, 
Kataoka et al. 2006), and also ILK-1 expression is deregulated (breast cancer), ILK1 signaling has 
the potential to contribute to therapy resistance. 
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Our data strongly suggest that ILK/AKT pathway have a crucial role not only in cancer 
progression and invasion but also in the resistance to the therapy. 
Our work shows that ILK-1 is implicated to the resistance of glioblastoma to anti-angiogenic 
drugs, in fact we found an increase of pAKT after the anti-angiogenic therapy. 
It has been shown that PI 3-kinase/ILK signaling is important in the morphological changes of 
endothelial cells. ILK may function as a component of a signal transduction pathway regulating 
endothelial cell survival mediated by PKB/Akt. This work demonstrated that ILK has the ability 
to support both chemotactic migration and cell proliferation mediated by VEGF in endothelial 
cells (Kaneko, Kitazato et al. 2004). Our work suggest that the pathway ILK/AKT is not only 
implicated in endothelial cells, in fact the inhibition of ILK-1 in endothelial cells alone or in 
combination with anti-angiogenic drugs is not enough to decrease the viability of these cells in 
short term treatment, instead it is able to decrease the viability of human glioma cells. In the in 
vivo experiments we have demonstrated that the combination of the anti-angiogenic treatment and 
inhibition of ILK-1 is able to cooperate and to reduces tumour volume and the recruitment of host 
vessels; this effects is greater in the tumour in witch ILK-1 is less active and less expressed. Little 
is known about the mechanisms. 
It has been demonstrated that overexpression of ILK-1 in melanoma cells (leads to an increase of 
VEGF expression due to an increase of HIF-1α activity.  
Since in our cellular glioma models we saw a decrease of viability and of AKT activation after the 
combination therapy with anti-angiogenic drugs plus QLT0267, but not with the anti-angiogenic 
drugs alone, we have checked the expression levels of HIF-1α in U87 cells after 6 hours of 
treatment to see if the effect that we saw in cellular models could explain what we have seen in 
the in vivo experiments. We found a strong decrease in HIF-1α expression in human glioma cells 
just when we treated with the combination of the two drugs. We think that the decrease of HIF1α 
expression lead to a decrease of VEGF secretion from tumoral cells and that this leads to a less 
stimulation of endothelial cells growth and less angiogenesis in our in vivo model. 
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